Biocrucible, a Sapphiros Company, Appoints Per Grufman as CEO

2023-01-20

高管变更

CAMBRIDGE, U.K., Jan. 20, 2023 /PRNewswire/ -- Biocrucible, a Sapphiros platform company dedicated to building the next generation of consumer diagnostics, announced the appointment of Per Grufman, Ph.D., as its Chief Executive Officer.

A biotech industry veteran of thirty years, Dr. Grufman will lead the development and commercialization of Biocrucible's isothermal amplification technologies for next-generation molecular diagnostics.

"Per's proven track record of rapidly bringing new products to market will be critical as Biocrucible moves into its next phase, delivering products to consumers globally," said Sapphiros CEO, Mark Gladwell.

Before joining Biocrucible, Dr. Grufman was Vice President of Research and Development for LumiraDx focusing on assay engineering and product lifecycle management. Prior to Lumira, Dr. Grufman served as Executive Director of Research and Development at Cepheid AB in Solna, Sweden, where he led the growth of the R&D organization, launching a broad portfolio of products.

Dr. Grufman earned his Ph.D. from the Department of Microbiology, Tumor, and Cell Biology (MTC) at the Karolinska Institutet in Sweden and his Master of Science in biology from the University of Stockholm.

"I am excited to join the Sapphiros family as CEO of Biocrucible," Grufman said. "Thanks to the disruptive suite of technologies Biocrucible's researchers have already assembled, we have the opportunity to deliver rapid diagnostics faster and closer to the patient."

About Biocrucible:

Biocrucible, a part of the Sapphiros portfolio of companies, develops high-performance molecular consumer diagnostics.

About Sapphiros:

Sapphiros, backed by Neoenta and KKR, is a privately-held consumer diagnostic portfolio company. The Sapphiros portfolio includes novel sample collection, next generation diagnostics, and extreme volume manufacturing to help consumers access important diagnostic results globally. Knowing Now Moves Us™

For further information: Sapphiros, [email protected]

SOURCE Sapphiros

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构